North America Glaucoma Therapeutics Market to 2031 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. North America Glaucoma Therapeutics Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. North America Glaucoma Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Mounting Incidence of Glaucoma Disease
5.1.2 Increasing Number of Product Launches, Collaborations, and Acquisitions

5.2 Market Opportunities

5.2.1 Development of Wearable Technologies

5.3 Future Trends

5.3.1 Development of Novel Drug Delivery Methods

5.4 Impact of Drivers and Restraints

6. North America Glaucoma Therapeutics Market Regional Analysis

6.1 North America Glaucoma Therapeutics Market Overview

6.2 North America Glaucoma Therapeutics Market Revenue 2025-2023 (US$ Million)

6.3 North America Glaucoma Therapeutics Market Forecast Analysis

7. North America Glaucoma Therapeutics Market Analysis – by Drug Class

7.1 Beta Blockers

7.1.1 Overview
7.1.2 Beta Blockers: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Alpha Adrenergic Agonists

7.2.1 Overview
7.2.2 Alpha Adrenergic Agonists: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Prostaglandins Analogues

7.3.1 Overview
7.3.2 Prostaglandins Analogues: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Carbonic Anhydrase Inhibitors

7.4.1 Overview
7.4.2 Carbonic Anhydrase Inhibitors: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

7.5 Combination Drugs

7.5.1 Overview
7.5.2 Combination Drugs: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Glaucoma Therapeutics Market Analysis – by Indication

8.1 Open Angle Glaucoma

8.1.1 Overview
8.1.2 Open Angle Glaucoma: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2023 (US$ Million)

8.2 Angle Closure Glaucoma

8.2.1 Overview
8.2.2 Angle Closure Glaucoma: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2023 (US$ Million)

9. North America Glaucoma Therapeutics Market Analysis – by Distribution Channel

9.1 Hospital Pharmacy

9.1.1 Overview
9.1.2 Angle Closure Glaucoma: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2023 (US$ Million)

9.2 Retail Pharmacy

9.2.1 Overview
9.2.2 Angle Closure Glaucoma: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2023 (US$ Million)

9.3 Online Pharmacy

9.3.1 Overview
9.3.2 Angle Closure Glaucoma: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2023 (US$ Million)

10. North America Glaucoma Therapeutics Market – North America Analysis

10.1 North America

10.1.1 North America Glaucoma Therapeutics Market Breakdown, by Key Country, 2021 and 2023 (%)
10.1.1.1 North America Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
10.1.1.1 US: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2023 (US$ Million)

10.1.1.1.1 US: North America Glaucoma Therapeutics Market Breakdown, by Drug Class
10.1.1.1.2 US: North America Glaucoma Therapeutics Market Breakdown, by Indication
10.1.1.1.3 US: North America Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10.1.1.2 Canada: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2023 (US$ Million)

10.1.1.2.1 Canada: North America Glaucoma Therapeutics Market Breakdown, by Drug Class
10.1.1.2.2 Canada: North America Glaucoma Therapeutics Market Breakdown, by Indication
10.1.1.2.3 Canada: North America Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10.1.1.3 Mexico: North America Glaucoma Therapeutics Market – Revenue and Forecast to 2023 (US$ Million)

10.1.1.3.1 Mexico: North America Glaucoma Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 Mexico: North America Glaucoma Therapeutics Market Breakdown, by Indication
10.1.1.3.3 Mexico: North America Glaucoma Therapeutics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. North America Glaucoma Therapeutics Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Alcon AG

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 AbbVie Inc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Bausch & Lomb Inc

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Fera Pharmaceuticals, LLC

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Viatris Inc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Novartis AG

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Sun Pharmaceutical Industries Ltd

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Teva Pharmaceuticals Industries Ltd

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Thea Pharma Inc

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Santen Pharmaceutical Co., Ltd

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights